On January 21^st, Yang Yong, Vice President of China Pharmaceutical University, led a delegation to Beijing GoBroad Hospital for the signing ceremony of the strategic cooperation agreement between China Pharmaceutical University and GoBroad Healthcare Group. Attendees included Wu Ruibin, Assistant to the President, Secretary of the Party Committee, and Director of the Management Committee of the Xuanwumen Campus; Sun Minjie, Director of the Academic Affairs Office and Dean of the Mudi Meng Honors College; Wang Xinran, Executive Vice Dean of the Modern Pharmaceutical Industry College; Li Jin, Chief Scientist of GoBroad Healthcare Group and President of Shanghai GoBroad Cancer Hospital; Professor Ma Jun, Director of the Harbin Hematology and Oncology Research Institute; Professor Qin Shukui, President of the Affiliated Nanjing Tianyinshan Hospital of China Pharmaceutical University; and Professor Zhu Jun, Party Secretary, Director of Internal Medicine, and Director of the Lymphoma Department at Peking University Cancer Hospital. The ceremony was hosted by Feng Chen, Vice President of GoBroad Healthcare Group.

At the meeting, Vice President Yang Yong introduced the development history of China Pharmaceutical University and highlighted the major accomplishments in teaching and education, scientific research, research platform construction, social services, and international and domestic cooperation in recent years. He noted that GoBroad Healthcare Group has achieved remarkable success in the fields of oncology and cellular immunotherapy. Yang Yong looks forward to both parties focusing on contemporary and practical needs, leveraging their respective strengths, and collaborating precisely in the training of pharmacy professionals from a clinical perspective and in clinical drug development. This collaboration aims to streamline the entire drug development process, and conduct organized research. He further emphasized the intention to embark on a new chapter of win-win cooperation in biomedical innovation, technology transfer, and cultivation of high-caliber talents.

The CEO of GoBroad Healthcare Group delivered a welcome speech, stating that GoBroad, in collaboration with a group of top experts with rich clinical experience and research capabilities, is committed to establishing a unique "Academic-driven clinical research organization." This endeavor aims to build an innovative medical ecosystem encompassing "Clinical discovery-basic research-industrial transformation-clinical application" to enhance the efficiency and quality of the biopharmaceutical industry's development. Through this collaboration with our university, both parties will jointly establish a high-level public service platform for clinical research, and leverage industrial momentum to cultivate a greater number of high-caliber pharmaceutical research talents suited for industry development. This partnership will form a closed-loop ecological system integrating "Medical care, industry, research, and finance," enhancing independent innovation capabilities in new drug development and serving more patients in China and globally.

Signing Ceremony

During the meeting, Vice President Yang Yong and Li Jin, Chief Scientist of GoBroad Healthcare Group and President of Shanghai GoBroad Cancer Hospital, signed the strategic cooperation agreement on behalf of both parties. According to the agreement, both parties will adhere to the principles of complementarity and mutual benefit, actively promoting the coordinated development of medical education, accelerating the exploration of new paradigms for the research and development of innovative drugs in China, and supporting the development of the biopharmaceutical industry and the construction of a healthy China.

Prior to the meeting, Vice President Yang Yong and his delegation also toured Beijing GoBroad Hospital.

It is reported that GoBroad Healthcare Group was founded in 2017, with a core focus on clinical diagnosis and treatment, clinical research, reference laboratories, and information technology. It stands as a pioneer in exploring the research-oriented hospital model in China and is committed to establishing a clinical-driven, innovative medical technology platform. Presently, it operates seven hospitals in Beijing, Shanghai, and Guangzhou, concentrating on specialized fields with active innovation such as solid tumors, hematological diseases, and neuroscience.